<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04807621</url>
  </required_header>
  <id_info>
    <org_study_id>FS52016</org_study_id>
    <nct_id>NCT04807621</nct_id>
  </id_info>
  <brief_title>Platelets or Fibrinogen as First-line Treatment for Bleeding During Pedatric Heart Surgery</brief_title>
  <official_title>Platelets or Fibrinogen as First-line Treatment for Bleeding During Pedatric Heart Surgery: a Randomized, Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to test whether platelet transfusion or fibrinogen concentrate is the most&#xD;
      effective treatment of intraoperative bleeding, when performing open heart surgery with&#xD;
      cardiopulmonary bypass on children with congenital heart defects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2018</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HEPTEM-A10</measure>
    <time_frame>45 minutes after intervention</time_frame>
    <description>The outcome measure is a measure of global coagulation efficacy, obtained by ROTEM analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of transfused packed red blood cells</measure>
    <time_frame>up to first postoperative morning</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Congenital Heart Disease</condition>
  <arm_group>
    <arm_group_label>Platelets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients recieve, in the presence of significant bleeding and pathological results of ROTEM analysis, a platelet transfusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fibrinogen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients recieve, in the presence of significant bleeding and pathological results of ROTEM analysis, fibrinogen concentrate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Platelet transfusion</intervention_name>
    <description>Platelets (10 ml/kg body weight) is transfused.</description>
    <arm_group_label>Platelets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fibrinogen concentrate</intervention_name>
    <description>Fibrinogen concentrate (300 mg/kg body weight) is administered.</description>
    <arm_group_label>Fibrinogen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children &lt; 1 years of age, scheduled for open surgery of congenital heart defects,&#xD;
             using cardiopulmonary bypass.&#xD;
&#xD;
          -  Body weight &lt; 10 kg.&#xD;
&#xD;
          -  Expected CPB time &gt; 90 minutes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known coagulation disorder, current treatment with antiplatelet and/or anticoagulant&#xD;
             drugs, major surgery the past month before the planned surgery, preoperative kidney or&#xD;
             liver failure (defined as creatinine and/or transaminases &gt; normal interval for the&#xD;
             patient´s age), gestational age &lt; 34 weeks.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fredrik Söderlund, MD</last_name>
    <phone>+46 31 343 6895</phone>
    <email>fredrik.soderlund@vgregion.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Birgitta Romlin, MD, PhD</last_name>
    <phone>+46 31 343 5370</phone>
    <email>birgitta.romlin@vgregion.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fredrik Söderlund, MD</last_name>
      <phone>+46733829802</phone>
      <email>fredrik.soderlund@vgregion.se</email>
    </contact>
    <contact_backup>
      <last_name>Birgitta Romlin, MD, PhD</last_name>
      <email>birgitta.romlin@vgregion.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 18, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Fredrik Söderlund</investigator_full_name>
    <investigator_title>Consultant, Anaesthesia and Intensive Care</investigator_title>
  </responsible_party>
  <keyword>Bleeding</keyword>
  <keyword>Coagulopathy</keyword>
  <keyword>Heart surgery</keyword>
  <keyword>Cardiopulmonary bypass</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

